CNTX
Context Therapeutics Inc. (NASDAQ)
Healthcare — Biotechnology
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Strong Buy
1.3 / 5
8 analysts
$0.61
+$0.05 (+9.75%)
Target:
$5.38
(784.0%)
Sign in to add CNTX to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $55.89M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.41 |
| EPS (TTM) | $-0.42 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -56.19% |
| Debt/Equity | 0.54 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $5.38 |
| Analysts | 8 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 11.7 |
| Beta | 1.61 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.62 |
| 52-Week Low | $0.55 |
| 50-Day Avg | $1.87 |
| 200-Day Avg | $1.77 |
| Avg Volume | $1.87M |
| Volume | $4.30M |
Performance Analysis
BULLISHCNTX shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($0.55), which could present a value opportunity.
+
RSI at 11.7 signals oversold conditions — a bounce may be ahead.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 8 analysts.
+
Average analyst target of $5.38 implies 784.0% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report